Molecular Cancer Therapeutics

Table of Contents

May 2014 • Volume 13 • Number 5

Highlights of This Issue 1019

REVIEW

1021  Picking the Point of Inhibition: A Comparative Review of PI3K/AKT/mTOR Pathway Inhibitors
Rodrigo Dienstmann, Jordi Rodon, Violeta Serra, and Josep Tabernero

SMALL MOLECULE THERAPEUTICS

1032  Enhancement of Nab-Paclitaxel Antitumor Activity through Addition of Multitargeting Antiangiogenic Agents in Experimental Pancreatic Cancer
Niranjan Awasthi, Changhua Zhang, Anna M. Schwarz, Stefan Hinz, Margaret A. Schwarz, and Roderich E. Schwarz

1044  The Phosphoinositide 3-Kinase α Selective Inhibitor BYL719 Enhances the Effect of the Protein Kinase C Inhibitor AEB071 in GNAQ/GNA11-Mutant Uveal Melanoma Cells
Elgilda Musi, Grazia Ambrosini, Elisa de Stanchina, and Gary K. Schwartz

1054  Centmitor-1, a Novel Acridinyl-Acetohydrazide, Possesses Similar Molecular Interaction Field and Antimitotic Cellular Phenotype as Rigosertib, ON 01910.Na

1067  Preclinical Evaluation of the Supercritical Extract of Azadirachta Indica (Neem) Leaves In Vitro and In Vivo on Inhibition of Prostate Cancer Tumor Growth
Qiang Wu, Manish Kohli, H. Robert. Bergen III, John C. Cheville, Jeffrey Kernes, Hong Cao, Charles Y.F. Young, Donald J. Tindall, Mark A. McNiven, and Krishna Vanaja Donkena

1078  Characterization of the Activity of the PI3K/mTOR Inhibitor XL765 (SAR245409) in Tumor Models with Diverse Genetic Alterations Affecting the PI3K Pathway

1092  UPARANT: A Urokinase Receptor–Derived Peptide Inhibitor of VEGF-Driven Angiogenesis with Enhanced Stability and In Vitro and In Vivo Potency
Maria Vincenza Carriero, Katia Bifulco, Michele Minopoli, Liliana Lista, Ornella Maglio, Luigi Mele, Gioconda Di Carluccio, Mario De Rosa, and Vincenzo Pavone

1105  Preclinical Pharmacological Evaluation of a Novel Multiple Kinase Inhibitor, ON123300, in Brain Tumor Models
Xiaoping Zhang, Hua Lv, Hong Cao, Manish Kohli, Rana Elkholi, Jerry E. Chipuk, M.V. Ramana Reddy, E. Premkumar Reddy, and James M. Gallo

1117  Characterization of the Novel and Specific PI3Kα Inhibitor NVP-BYL719 and Development of the Patient Stratification Strategy for Clinical Trials

1130  Protein Kinase D as a Potential Chemotherapeutic Target for Colorectal Cancer
Ning Wei, Edward Chu, Peter Wipf, and John C. Schmitz

Downloaded from mct.aacrjournals.org on July 6, 2017. © 2014 American Association for Cancer Research.
Aurora Kinase Inhibition Induces PUMA via NF-xB to Kill Colon Cancer Cells
Jing Sun, Kyle Knickelbein, Kan He, Dongshi Chen, Crissy Dudgeon, Yongqian Shu, Jian Yu, and Lin Zhang

Nuclear Translocation of Hand-1 Acts as a Molecular Switch to Regulate Vascular Radiosensitivity in Medulloblastoma Tumors: The Protein uPAR Is a Cytoplasmic Sequestration Factor for Hand-1
Swapna Asuthkar, Venkateswara Rao Gogineni, Jasti S. Rao, and Kiran Kumar Velpula

The G Protein–Coupled Receptor GALR2 Promotes Angiogenesis in Head and Neck Cancer
Rajat Banerjee, Elizabeth A. Van Tubergen, Christina S. Scanlon, Robert Vander Broek, Joel P. Lints, Min Liu, Nickole Russo, Ronald C. Inglehart, Yugang Wang, Peter J. Polverini, Keith L. Kirkwood, and Nisha J. D’Silva

The Role of Gene Body Cytosine Modifications in MGMT Expression and Sensitivity to Temozolomide
Erika L. Moen, Amy L. Stark, Wei Zhang, M. Eileen Dolan, and Lucy A. Godley

ERBB3/HER2 Signaling Promotes Resistance to EGFR Blockade in Head and Neck and Colorectal Cancer Models
Li Zhang, Carla Castanaro, Bo Luan, Katie Yang, Liangfen Fan, Jeanette L. Fairhurst, Ashique Rafique, Terra B. Potocky, Jing Shan, Frank J. Dellino, Ergang Shi, Tammy Huang, Joel H. Martin, Gang Chen, Douglas MacDonald, John S. Rudge, Gavin Thurston, and Christopher Daly

Nuclear Epidermal Growth Factor Receptor Is a Functional Molecular Target in Triple-Negative Breast Cancer
Toni M. Brand, Mari Iida, Emily F. Dunn, Neha Luthar, Kellie T. Kostopoulos, Kelsey L. Corrigan, Matthew J. Wleklinski, David Yang, Karri B. Wisinski, Ravi Salgia, and Deric L. Wheeler

Metallothionein 1G and Zinc Sensitize Human Colorectal Cancer Cells to Chemotherapy
Juan M. Arriaga, Angela Greco, José Mordoh, and Michele Bianchini

COMPANION DIAGNOSTICS AND CANCER BIOMARKERS

Concordance of Genomic Alterations between Primary and Recurrent Breast Cancer
ABOUT THE COVER

Angiogenesis is important for tumor progression. In squamous cell carcinoma of the head and neck (SCCHN), angiogenesis is activated by cytokines including IL-6 and VEGF. Galanin receptor 2 (GALR2) is a G protein-coupled receptor that induces aggressive growth in SCCHN. GALR2 stimulates tumor angiogenesis in SCCHN via p38-mediated inhibition of tristetraprolin (TTP) with resultant enhanced cytokine secretion. Given that p38 inhibitors are in clinical use for inflammatory disorders, GALR2/p38-mediated cytokine secretion may be an excellent target for new adjuvant therapy in SCCHN. For details, see article by Banerjee, Van Tubergen, and colleagues on page 1323.